Ameliorative potential of gemfibrozil and silymarin on experimentally induced nephrotoxicity in rats  by Kabel, A.M. et al.
African Journal of Urology (2013) 19, 171–178
Pan African Urological Surgeons’ Association
African  Journal  of  Urology
www.ees.elsevier.com/afju
www.sciencedirect.com
Ameliorative  potential  of  gemfibrozil  and  silymarin  on
experimentally induced  nephrotoxicity  in  rats
A.M.  Kabel a,∗,  H.A.  Mahmoud a,  S.S.  El  Kholy b
a Pharmacology  Department,  Faculty  of  Medicine,  Tanta  University,  Egypt
b Physiology  Department,  Faculty  of  Medicine,  Tanta  University,  Egypt
Received 16 February 2013; received in revised form 5 April 2013; accepted 5 April 2013
KEYWORDS
Gemfibrozil;
Silymarin;
Nephrotoxicity;
Rats;
Cisplatin
Abstract
Introduction:  Acute nephrotoxicity is a frequent complication of critical illness especially in the inpa-
tient setting. Cisplatin is one of the most active anticancer drugs. Nephrotoxicity is the most common
side effect associated with cisplatin treatment. Silymarin is widely used for hepatic disorders due to its
antioxidant and anti-inflammatory properties. Gemfibrozil, a hypolipidemic drug, has also antioxidant and
anti-inflammatory properties.
Objective: To detect the effect of gemfibrozil and silymarin either alone or in combination on cisplatin-
induced nephrotoxicity in rats.
Subjects and  methods:  Fifty albino rats were divided into 5 equal groups: Control untreated group,
cisplatin treated group, gemfibrozil + cisplatin treated group, silymarin + cisplatin treated group, gemfi-
brozil + silymarin + cisplatin treated group. Blood urea, serum creatinine, creatinine clearance, urinary
N-acetyl beta-d-glucosaminidase, urinary protein, tissue superoxide dismutase, malondialdehyde, reduced
glutathione, tumour necrosis factor alpha and mitochondrial complex I activity were determined. Kidneys
were excised for histopathological examination.
Results:  Gemfibrozil and/or silymarin efficiently attenuated cisplatin-induced nephrotoxicity evidenced byea, serum creatinine, urinary N-acetyl beta-d-glucosaminidase, urinary pro-
nd tissue tumour necrosis factor alpha with significant increase in creatinine
thione, tissue superoxide dismutase and mitochondrial complex I activity
f the necrotic damage and progressively increasing apoptotic index assessed
ination compared to the cisplatin treated group.significant decrease in blood ur
tein, tissue malondialdehyde a
clearance, tissue reduced gluta
simultaneous with reduction o
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Conclusion:  The combination of gemfibrozil and silymarin has protective effects against cisplatin-induced
nephrotoxicity in rats better than each of these drugs alone due to anti-inflammatory and antioxidant
properties of the used drugs.
© 2013 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. 
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idneys are vulnerable to damage by toxins, infection, immune
eactions and ischaemia. Acute renal failure is a frequent compli-
ation of critical illness especially in the inpatient setting [1]. The
rognosis of acute renal failure is complicated by secondary injuries
nduced by free radicals formed during ischaemia/reperfusion injury
f the kidney [2].
isplatin, anticancer drug, is one of the most active drugs used in
reatment of tumours such as testicular, bladder, lung, stomach and
varian cancers [3]. Cisplatin can be used as a model for nephrotox-
city [4]. The mechanisms of cisplatin nephrotoxicity are still not
ully understood. The nephrotoxicity of cisplatin seems to be due to
ell membrane peroxidation, mitochondrial dysfunction, inhibition
f protein synthesis, DNA damage, changes in the pro-apoptotic
ax protein and inhibition of the antioxidant system by pro-oxidant
amage to the renal tissue [5,6]. Previous reports have demonstrated
rotective roles for antioxidants and free radical scavengers such
s vitamin E, lipoic acid and N-acetylcysteine in cisplatin-induced
cute nephrotoxicity [7].
ilymarin is the active ingredient of milk thistle. Several studies
roved that silymarin has antioxidant and anti-inflammatory proper-
ies [8,9]. Silymarin is widely used for hepatic and biliary disorders
nd is under trial for treatment of renal disorders [10].
emfibrozil is a fibrate medication considered as one of peroxisome
roliferator-activated receptors alpha (PPAR-) agonists used along
ith a proper diet to lower triglycerides and cholesterol in the blood
11]. Li et al. [12] reported that PPAR-  inhibit fatty acid oxida-
ion. Some trials have been performed by Li et al. [13] showed
hat fibrates have antioxidant and anti-inflammatory properties that
elp in healing and wound repair. For all these reasons, study of
he effects of gemfibrozil and silymarin on experimentally induced
ephrotoxicity is of particular interest. The aim of this work was
o detect the effect of gemfibrozil and silymarin either alone or in
ombination on cisplatin-induced nephrotoxicity in rats.
ubjects  and  methods
rugs used
 Cisplatin  vial 10 mg/10 ml (Merck); was administered intraperi-
toneally in a dose of 20 mg/kg body weight [13].
 Gemfibrozil  tablets (Lopid, Alkan pharma); was administered
orally in a dose of 100 mg/kg body weight, prepared as 10 mg/ml
in 0.5% Carboxy methyl cellulose solution [14].
 Silymarin  powder (Sedico, Egypt); was administered orally as
a suspension in a dose of 100 mg/kg body weight, prepared as
10 mg/ml in 0.5% Carboxy methyl cellulose solution [15].
o
w
a
gnimals used  and  experimental  design
n this work, we used 50 albino rats of both sexes weighting
50–200 g. All the experiments were conducted according to the
ational Research Council’s guidelines. Animal handling was fol-
owed according to the principles of laboratory animal care (NIH
ublication #85-23, revised in 1985). Rats were housed in animal
aboratory room, had free access to water and food all over the
eriod of the work. The duration of the experiment was 18 days.
he animals were divided into 5 equal groups as follows:
 Group (1): Control untreated group.
 Group (2): Nephrotoxicity induced group, received cisplatin
intraperitoneally in a dose of 20 mg/kg body weight (single dose).
 Group (3): Received gemfibrozil orally in a dose of 100 mg/kg
body weight once daily for 14 days then received cisplatin
intraperitoneally in a dose of 20 mg/kg body weight (single dose).
 Group (4): Received silymarin orally in a dose of 100 mg/kg body
weight once daily for 14 days then received cisplatin intraperi-
toneally in a dose of 20 mg/kg body weight (single dose).
 Group (5): Received gemfibrozil orally in a dose of 100 mg/kg
body weight once daily concomitant with silymarin orally in
a dose of 100 mg/kg body weight once daily for 14 days then
received cisplatin intraperitoneally in a dose of 20 mg/kg body
weight (single dose).
t the end of the experimental period (3 days after cisplatin injec-
ion), the animals were kept in individual metabolic cages for 24-h
rine collection. The collected urine was analyzed for protein con-
ent according to the sulfosalicylic acid colorimetric method [16],
-acetyl beta-d-glucosaminidase (NAG) activity according to the
ethod of Price [17], and creatinine concentration according to the
ethod of Henry [18].
n the following day, blood samples were taken by retro-orbital
ethod to estimate blood urea according to the method of Patton and
rouch [19] and serum creatinine according to the method of Henry
18]. According to the 24 h urine volume, urinary creatinine and
erum creatinine concentration, creatinine clearance was calculated
y applying the following formula [20]:
reatinine clearance (ml/min) = mg creatinine/dl urine × ml urine 24 h
mg creatinine/dl serum × 1440
ats were sacrificed by decerebration and both kidneys were
emoved and sectioned for histopathological analysis [21]. The
emaining kidney tissue was homogenized for determination of mal-
ndialdehyde (MDA) according to the method based on the reaction
ith thiobarbituric acid [22], superoxide dismutase (SOD) activity
ccording to the method of Marklund and Marklund [23], reduced
lutathione (GSH) according to the method of Beutler et al. [24],
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total protein content according to the method of Lowry et al. [25]
and tissue TNF-  using ELISA kits supplied by RayBiotech, Inc.
Preparation  of  the  rat  kidney  mitochondria
A part of the kidney was collected in a special medium obtained
by dissolving 10.94 g sucrose, 1.21 g Tris–HCl, and 0.38 g EGTA
in 100 ml distilled water and pH was adjusted to 7.8. Homogeniza-
tion was done in 9 volumes of this cold medium with three or four
strokes. Then, the homogenate was centrifuged at 700 ×  g  for 10 min
at 4 ◦C, the supernatant was centrifuged for 20 min at 1000 ×  g  to
obtain mitochondria pellets that were washed with the previous col-
lecting buffer to remove microsomal and cellular contamination.
Then, mitochondria were resuspended in 9 volumes of the collect-
ing buffer [26]. Mitochondrial protein was determined using Lowry
method [25]. Then, mitochondrial complex I activity was measured
according to the method of Birch-Machin et al. [27].
Measurement  of  the  apoptotic  index
Apoptotic index (AI) was defined as aggregate percentages of apop-
totic cells and/or apoptotic bodies per total number of cells (1000
cells counted) in 10 randomly selected high power fields (400×).
The counting was performed by one pathologist, and in 20% of
randomly selected cases the counting was repeated by another
pathologist. In cases with significant disagreement between results,
the counting was performed at the multiheaded microscope by
both pathologists. The morphological criteria for apoptotic bod-
ies were applied in our study according to Staunton and Gaffney
[28] as follows: (1) a single rounded mass with condensed, strongly
eosinophilic cytoplasm with a single clump of strongly basophilic
material representing chromatin condensation; (2) a similar to the
previously mentioned structure but with condensed chromatin, frag-
mented into more than one piece; (3) fragments of condensed
chromatin without surrounding cytoplasm. The apoptotic bodies
most frequently appear as single structures separated from the sur-
rounding intact cells by a clear halo. Clusters of minute apoptotic
bodies were counted as one. Apoptotic bodies were not counted in
necrotic areas. Equivocal apoptotic bodies were not counted.
Statistical  analysisData were presented as mean ±  SEM. Data were statistically ana-
lyzed by computer SPSS 15 software. Data were analyzed by one
way analysis of normality of variance (ANOVA). Independent sam-
ple t-test and Covariate test were used as statistical tests. Differences
-
Table  1  Effect of administration of gemfibrozil, silymarin and their comb
protein and urinary NAG and urinary in cisplatin treated rats.
Control Cisplatin Gem
Blood urea (mg/dl) 20.2 ± 0.67 77.12 ± 2.83* 52.
Serum creatinine (mg/dl) 0.25 ± 0.01 1.23 ± 0.04* 0.
Creatinine clearance (ml/min/day) 1.24 ± 0.03 0.44 ± 0.01* 0.
Urinary NAG (U/L) 0.23 ± 0.01 1.26 ± 0.02* 0.
Urinary protein (mg/dl) 0.56 ± 0.02 1.69 ± 0.07* 1.
Values were represented as mean ± SEM. Number of rats in each group = 10.
* Significant compared to the control group (P value less than 0.05).
# Significant compared to cisplatin group (P value less than 0.05).
$ Significant compared to gemfibrozil + cisplatin group (P value less than 0.0
• Significant compared to silymarin + cisplatin group (P value less than 0.05)173
etween the means of different groups were considered significant
t a level of P-value less than 0.05.
esults
ffect of  different  treatments  on  blood  urea,  serum  creatinine  and
reatinine  clearance  (Table  1)
 Administration of cisplatin to rats resulted in significant increase
in blood urea and serum creatinine with significant decrease in
creatinine clearance compared to the control untreated group.
 Administration of silymarin and/or gemfibrozil to rats before cis-
platin administration resulted in significant decrease in blood
urea and serum creatinine with significant increase in creatinine
clearance compared to cisplatin treated group.
 The decrease in blood urea and serum creatinine and the increase
in creatinine clearance were more significant in silymarin and
gemfibrozil combination group compared to the use of each drug
individually.
ffect  of  different  treatments  on  urinary  NAG  and  urinary  protein
Table  1)
 Administration of cisplatin to rats resulted in significant increase
in urinary NAG and urinary protein compared to the control
untreated group.
 Administration of silymarin and/or gemfibrozil to rats before cis-
platin administration resulted in significant decrease in urinary
NAG and urinary protein compared to cisplatin treated group.
 The decrease in urinary NAG and urinary protein was more signif-
icant in silymarin and gemfibrozil combination group compared
to the use of each drug individually.
ffect  of  different  treatments  on  the  antioxidant  status  (Table  2)
 Administration of cisplatin to rats resulted in significant increase
in tissue MDA with significant decrease in tissue GSH and tissue
SOD compared to the control untreated group.
 Administration of silymarin and/or gemfibrozil to rats before cis-
platin administration resulted in significant decrease in tissue
MDA with significant increase in tissue GSH and tissue SOD
compared to cisplatin treated group.
 The decrease in tissue MDA and the increase in tissue GSH and
tissue SOD were more significant in silymarin and gemfibrozil
combination group compared to the use of each drug individually.
ination on blood urea, serum creatinine, creatinine clearance, urinary
fibrozil + cisplatin Slymarin + cisplatin Gemfibrozil + slymarin
+ cisplatin
41 ± 2.77# 47.64 ± 2.23# 37.4 ± 1.15#,$,•
69 ± 0.02# 0.57 ± 0.03# 0.47 ± 0.02#,$,•
68 ± 0.02# 0.73 ± 0.02# 0.87 ± 0.04#,$,•
76 ± 0.02# 0.65 ± 0.02# 0.49 ± 0.01#,$,•
19 ± 0.06# 0.98 ± 0.03# 0.86 ± 0.04#,$,•
5).
.
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Table  2  Effect of administration of gemfibrozil, silymarin and their combination on different oxidative stress biomarkers (Renal SOD, GSH,
MDA), tissue TNF-  and mitochondrial complex I activity in cisplatin treated rats.
Control Cisplatin Gemfibrozil + cisplatin Slymarin + cisplatin Gemfibrozil + slymarin
+ cisplatin
Renal SOD (U/g protein) 742.3 ± 8.5 287.15 ± 4.4* 486.2 ± 8.21# 544.11 ± 6.08# 595.51 ± 6.2#,$,•
Renal GSH (mol/g) 4.3 ± 0.04 2.44 ± 0.07* 3.54 ± 0.06# 3.41 ± 0.05# 3.82 ± 0.04#,$,•
Renal MDA (nmol/mg protein) 0.35 ± 0.02 1.51 ± 0.02* 0.63 ± 0.03# 0.72 ± 0.01# 0.58 ± 0.02#,$,•
Renal TNF- (pg/g tissue) 216.01 ± 6.75 1320.5 ± 22.5* 813.65 ± 9.03# 740.65 ± 9.76# 604.7 ± 16.2#,$,•
Mitochondrial complex I activity
(nmol NADH/min/mg protein)
94.7 ± 2.13 36.92 ± 1.45* 62.78 ± 2.4# 53.62 ± 3.2# 71.54 ± 1.8#,$,•
Values were represented as mean ± SEM. Number of rats in each group = 10.
* Significant compared to the control group (P value less than 0.05).
# Significant compared to cisplatin group (P value less than 0.05).
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the pathophysiology of cisplatin-induced nephrotoxicity [34,35]. In
particular, alterations in renal haemodynamics with vasoconstriction
leading to decreased renal blood flow after cisplatin administration
Figure  1  H&E stained sections from the kidney of control untreated
group with normal appearance of the glomeruli, tubules and interstitium.$ Significant compared to gemfibrozil + cisplatin group (P value less tha
• Significant compared to silymarin + cisplatin group (P value less than 
ffect  of  different  treatments  on  tissue  TNF-  (Table  2)
 Administration of cisplatin to rats resulted in significant increase
in tissue TNF-  compared to the control untreated group.
 Administration of silymarin and/or gemfibrozil to rats before cis-
platin administration resulted in significant decrease in tissue
TNF-  compared to cisplatin treated group.
 The decrease in tissue TNF-  was more significant in silymarin
and gemfibrozil combination group compared to the use of each
drug individually.
ffect  of  different  treatments  on  mitochondrial  complex  I activity
Table  2)
 Administration of cisplatin to rats resulted in significant decrease
in mitochondrial complex I activity compared to the control
untreated group.
 Administration of silymarin and/or gemfibrozil to rats before
cisplatin administration resulted in significant increase in mito-
chondrial complex I activity compared to cisplatin treated group.
 The increase in mitochondrial complex I activity was more signif-
icant in silymarin and gemfibrozil combination group compared
to the use of each drug individually.
istopathological  findings
he kidneys of the control rats had normal morphology with nor-
al appearance of the glomeruli, tubules and interstitium (Fig. 1).
athological evidence of kidney damage was observed in all rats
reated with cisplatin (Fig. 2) as indicated by diffuse tubular degen-
ration, focal necrosis, diffuse cellular infiltration and haemorrhage.
his picture was significantly improved in rats given gemfibrozil
lone or silymarin alone or both as evidenced by decrease in the
umber of infiltrated cells, haemorrhage, tubular degeneration and
ecrosis (Figs. 3–5) with progressively increasing apoptotic index
Table 3).
iscussion
isplatin is a chemotherapeutic drug that is widely used for can-
er treatment. However, cisplatin-induced nephrotoxicity is one of
he most common side effects. More than 25% of patients develop
cute nephrotoxicity after receiving cisplatin due to its accumula-
ion within the proximal tubular cells of the kidney [6,29,30]. Several
F
g5).
.
actors including inflammation, toxic damage and cell cycle arrest
ad been incriminated in the pathogenesis of cisplatin nephrotoxic-
ty [31]. Oxidative stress caused by increased generation of reactive
xygen species (ROS) had been suggested to play the major role in
isplatin nephrotoxicity [32,33].
any studies reported that inflammation plays an important role inigure  2  H&E stained sections from the kidney of cisplatin treated
roup with diffuse tubular degeneration, necrosis and haemorrhage.
Gemfibrozil and silymarin effect on nephrotoxicity 175
Figure  3  H&E stained sections from the kidney of gemfi-
brozil + cisplatin treated group with apparently normal glomeruli, focal
tubular degeneration and minimal tubular necrosis.
Figure  4  H&E stained sections from the kidney of sily-
marin + cisplatin treated group with apparently normal glomerul, mild
dilatation and necrosis of the tubules.
Figure  5  H&E stained sections from the kidney of gemfi-
brozil + silymarin + cisplatin treated group with apparently normal
Table  3  Apoptotic indices for kidney sections from rats treated
with gemfibrozil alone or silymarin alone or their combination.
Group Apoptotic index (%)
Cisplatin 1.4 ± 0.09
Gemfibrozil + cisplatin 4.3 ± 0.23#
Silymarin + cisplatin 3.9 ± 0.17#
Gemfibrozil + silymarin + cisplatin 5.3 ± 0.27#,• ,$
Apoptotic index (%) was calculated for sections of the kidney (values
presented as the mean ± SEM of an average of 10 fields).
# Significant compared to cisplatin group (P value less than 0.05).
$ Significant compared to gemfibrozil + cisplatin group (P value less
than 0.05).
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tion of this side-effect. Krey et al. [47] reported that gemfibrozil,
in contrast to the other fibrates, fails to bind and activate per-glomeruli and mild dilatation of the tubules.
[36]. Li et al. [13] showed that cisplatin increased the expression
of proinflammatory cytokines such as TNF-  and interleukin-6 (IL-
6), which are involved in various forms of inflammatory responses
which agree with the results of this current work where there was
significant increase in TNF-  associated with cisplatin induced
nephrotoxicity.
o
b• Significant compared to silymarin + cisplatin group (P value less than
0.05).
any studies had suggested that free radicals and oxidative stress
ere involved in cisplatin-induced nephrotoxicity due to depletion
f glutathione and decreased activities of the antioxidant enzymes
n the kidney [37]. These results were in agreement with the results
f this work where there was significant decrease in tissue SOD
nd GSH with significant increase in tissue MDA with severe tubu-
ar necrosis as evidenced by renal histopathological examination.
reatment with antioxidants such as vitamin E before and after
he cisplatin could significantly prevent the depletion of the renal
ntioxidant systems [38].
n the present study, it was observed that cisplatin induced signifi-
ant increase in blood urea, serum creatinine, urinary NAG, urinary
rotein, tissue MDA and tissue TNF-  with significant decrease
n creatinine clearance, tissue GSH, tissue SOD and mitochondrial
omplex I activity compared to the control untreated group. These
esults were in agreement with those of Mora et al. [39], Karimi
t al. [40], Li et al. [13] and ˙Is¸eri et al. [41]. They attributed this sig-
ificant increase in blood urea, serum creatinine, urinary NAG and
rinary protein and the significant decrease in creatinine clearance
o the decrease in glomerular filtration rate and renal blood flow and
ubular necrosis.
emfibrozil is one of fibrates that increases the activity of per-
xisome proliferator-activated receptor-alpha (PPAR-), a receptor
hich is involved in the metabolism of carbohydrates and fats, as
ell as adipose tissue differentiation [13]. Daynes and Jones [42]
uggested that PPAR plays an important role in the modulation
f inflammatory responses. The role of PPAR-  in the control of
nflammation was suggested from the observation that the inflamma-
ory response induced by leukotriene B4 was prolonged in PPAR-
eficient mice [43]. In another study, the administration of fibrates
o patients with moderate hyperlipidemia decreased plasma con-
entrations of proinflammatory cytokines such as IL-6, TNF-  and
cute-phase proteins [44].
ttallah et al. [45] had shown that prophylactic administration of
tatins, which also are considered as PPAR-  agonists, resulted
n less contrast nephropathy in patients that received a contrast
gent. On the other hand, Broeders et al. [46] showed that treat-
ent with fenofibrate, bezafibrate, and ciprofibrate might induce
enal dysfunction while gemfibrozil appeared to be an excep-xisome proliferator-activated receptors. These receptors, once
ound by fibrates, down-regulate the expression of the inducible
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yclooxygenase-2 enzyme which may be the cornerstone for the
aintenance of the vasodilator prostaglandins in the kidneys. In
upport of this hypothesis, clofibrate and ciprofibrate, but not gem-
brozil, were found to inhibit the production of the vasodilator
rostaglandins [48,49].
n the present study, treatment of rats with gemfibrozil before
isplatin administration efficiently attenuated acute nephrotoxicity
nduced by cisplatin evidenced by significant decrease in blood urea,
erum creatinine, urinary NAG, urinary protein, tissue MDA and tis-
ue TNF-  with significant increase in creatinine clearance, tissue
SH, tissue SOD and mitochondrial complex I activity compared
o cisplatin treated group. Also, there was reduction of the necrotic
amage and induction of apoptosis assessed by renal histopatholog-
cal examination.
hese results were in agreement with those of Portilla et al. [50],
i et al. [12] and Li et al. [13] who attributed this significant
mprovement in the disturbed biochemical parameters and reduc-
ion of necrotic damage assessed by histopathological examination
o that gemfibrozil is one of PPAR-  ligands which were shown to
educe the cisplatin-mediated increase in the inflammatory response
nd NF-kB binding activity which results in suppression of NF-kB-
ediated target gene activation including cytokines (TNF-, IL-6),
dhesion molecules and enzymes (Inducible nitric oxide synthase
nd cyclooxygenase) [51,52]. PPAR-  ligands can also repress tran-
cription of interleukin-6 promoter activity. So, PPAR-  interferes
ith different steps of the inflammatory response induced by cis-
latin and prevents neutrophil infiltration, suggesting that this could
epresent a mechanism for cytoprotection in cisplatin-mediated
ephrotoxicity.
agothu et al. [53] suggested that pretreatment with bezafibrate, one
f PPAR-  ligands prevented both the inhibition of PPAR-  activity
nd the accumulation of nonesterified free fatty acids induced by
isplatin. Also, bezafibrate prevented cisplatin-induced release of
ytochrome-C from the mitochondria to the cytosol.
i et al. [12] suggested that PPAR-  ligands ameliorate cisplatin
ephrotoxicity by inhibition of medium chain fatty acid oxidation
nd pyruvate dehydrogenase complex activity in the kidney tissue
ue to reduction of mRNA levels and enzyme activity of mito-
hondrial medium chain acyl-CoA dehydrogenase and pyruvate
ehydrogenase complex.
ilymarin is a flavonoid that is used clinically to treat chronic inflam-
atory liver disease and hepatic cirrhosis. The hepatoprotective
ffect of silymarin can be attributed to its antioxidant properties
y scavengering free radicals and increasing intracellular concen-
ration of glutathione [54]. Silymarin also has anti-inflammatory
roperties that regulate inflammatory mediators such as TNF-  [8],
itrous oxide and interleukins [55]. Fortunately, Turgut et al. [15]
bserved that therapy with silibinin, the main constituent of sily-
arin, had no effect on renal functions of normal rats but improves
enal functions in the diseased kidney.
n the present study, treatment of rats with silymarin before cisplatin
dministration efficiently attenuated acute nephrotoxicity induced
y cisplatin evidenced by significant decrease in blood urea, serum
reatinine, urinary NAG, urinary protein, tissue MDA and tissue
NF- with significant increase in creatinine clearance, tissue
SH, tissue SOD and mitochondrial complex I activity comparedA.M. Kabel et al.
o cisplatin treated group. This was concomitant with reduction
f the necrotic damage and induction of apoptosis assessed by
istopathological examination.
hese results were in agreement with those of Gaedeke et al. [56],
arimi et al. [40], Turgut et al. [15] and Abdel-Gawad and Mohamed
10]. They attributed this significant improvement in the disturbed
iochemical parameters and reduction of necrotic damage to the
nti-oxidant effect of silymarin and membrane-stabilizing proper-
ies that have already been proved in kidney cells challenged with a
ariety of radical-generating drugs. Silymarin may inhibit lipid per-
xidation by scavenging free radicals and increasing intracellular
oncentration of glutathione. Soto et al. [57] reported that the pro-
ective effect of silymarin on pancreatic damage induced by alloxan
ay be due to an increase in the activity of antioxidant enzymes.
liveira et al. [58] reported that silymarin protects liver against
schaemia/reperfusion injury by induction of the antioxidant enzyme
ystem. In agreement with these previous studies, the present study
bserved that silymarin has antioxidant effect and protect kidney
gainst cisplatin induced nephrotoxicity.
t was indicated that superoxide anions inactivate nitric oxide and
hat nitric oxide-dependent vascular relaxation is enhanced by super-
xide dismutase. Silymarin maintained renal blood flow as a result of
reserved nitric oxide through scavenging of the superoxide anions
59]. Manna et al. [8], Saliou et al. [60] and Toklu et al. [9] observed
hat silymarin has anti-inflammatory properties by blocking TNF-
-induced activation of the transcription factor NF-B.
reatment of rats with silymarin simultaneously with gemfi-
rozil before cisplatin administration efficiently attenuated cisplatin
ephrotoxicity as evidenced by significant decrease in blood urea,
erum creatinine, urinary NAG, urinary protein, tissue MDA and tis-
ue TNF-  with significant increase in creatinine clearance, tissue
SH, tissue SOD and mitochondrial complex I activity and signif-
cant reduction of tubular necrosis and cellular infiltration together
ith induction of apoptosis compared to the use of gemfibrozil or
ilymarin alone. The mechanism of this synergistic nephroprotec-
ive effect seems to be due to anti-inflammatory and antioxidant
roperties of the used drugs.
n conclusion, the results of this work indicated that the combi-
ation of gemfibrozil and silymarin had protective effects against
isplatin nephrotoxicity in rats better than each of these drugs alone.
his might provide a basis for the development of novel thera-
eutic strategies for protection against damage caused by cisplatin
dministration.
onflict of  interest
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